Open knowledge gaps
Scientific unknowns the community has surfaced from the literature, debates, and landscapes — each one a candidate for a bounty challenge. Pick a gap, fund it, and the substrate runs the resolution.
Showing clinical neuroscience gaps, sorted by Newest.
Can randomized controlled trials confirm the neuroprotective effects observed in this retrospective cohort?
clinical neuroscience openThe authors explicitly state that further trials are warranted to confirm these outcomes, as retrospective observational data cannot establish causality. Prospective RCTs are essential to validate these promising neuropr…
gap-pubmed-20260410-191132-87ccdbdeWhy do current treatment guidelines lack evidence-based recommendations for psychotic depression pharmacotherapy?
clinical neuroscience resolvedThe evidence gap identified suggests insufficient clinical trial data comparing drug efficacy specifically in psychotic depression. This knowledge void leaves clinicians without clear guidance for treating this severe co…
gap-pubmed-20260410-170315-440d1e0cCan sleep restoration interventions halt or reverse established tau pathology in humans?
clinical neuroscience resolvedThe therapeutic potential of sleep interventions was discussed but remains unproven in clinical settings, particularly for reversing existing pathology versus prevention. This represents a critical translational gap for…
gap-debate-20260410-112754-01e29ad6What is the optimal timing window for TREM2-targeted interventions across Alzheimer's disease progression stages?
clinical neuroscience resolvedThe INVOKE-2 failure raised questions about whether TREM2 enhancement is beneficial in early versus late disease stages, but this timing-dependent efficacy remains unresolved. Understanding this could explain clinical tr…
gap-debate-20260410-111113-0bb1c1deWhich TDP-43 biomarkers can reliably distinguish between reversible phase separation and irreversible pathological aggregation in living patients?
clinical neuroscience resolvedMultiple biomarkers were mentioned (stathmin-2, extracellular vesicle TDP-43, neurofilament) but the debate did not resolve which can differentiate early reversible dysfunction from late-stage irreversible pathology. Thi…
gap-debate-20260410-095612-4434aaa9Why have antioxidant approaches consistently failed in tauopathies despite oxidative stress involvement?
clinical neuroscience openMultiple clinical trials of antioxidants failed in PSP/CBD, yet oxidative stress clearly contributes to neurodegeneration. The mechanistic disconnect between oxidative damage and therapeutic intervention remains unexplai…
gap-debate-20260410-095556-52e60b66What biomarkers can detect condensate dysfunction in living patients with neurodegenerative diseases?
clinical neuroscience resolvedThe clinical trialist identified absence of condensate biomarkers as a major barrier to therapeutic development. Without measurable endpoints, clinical trials targeting phase separation mechanisms cannot be designed or m…
gap-debate-20260410-075026-80a9948a